Found: 50
Select item for more details and to access through your institution.
MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells.
- Published in:
- Cancer Cell International, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12935-024-03437-8
- By:
- Publication type:
- Article
Eosinophilic Dermatosis of Hematologic Malignancy: Emerging Evidence for the Role of Insect Bites—A Retrospective Clinico-Pathological Study of 35 Cases.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 10, p. 2935, doi. 10.3390/jcm13102935
- By:
- Publication type:
- Article
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 5, p. 982, doi. 10.1002/ajh.27247
- By:
- Publication type:
- Article
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
- Published in:
- Cancers, 2024, v. 16, n. 6, p. 1228, doi. 10.3390/cancers16061228
- By:
- Publication type:
- Article
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3249
- By:
- Publication type:
- Article
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3216
- By:
- Publication type:
- Article
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44039-0
- By:
- Publication type:
- Article
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44039-0
- By:
- Publication type:
- Article
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 2993, doi. 10.3390/cancers15112993
- By:
- Publication type:
- Article
Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. E24, doi. 10.1002/ajh.26779
- By:
- Publication type:
- Article
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.917115
- By:
- Publication type:
- Article
Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 8, p. 2076, doi. 10.3390/jcm11082076
- By:
- Publication type:
- Article
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E95, doi. 10.1002/ajh.26437
- By:
- Publication type:
- Article
Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.837531
- By:
- Publication type:
- Article
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 207, doi. 10.3390/cancers14010207
- By:
- Publication type:
- Article
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 570, doi. 10.1002/hon.2899
- By:
- Publication type:
- Article
CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4239, doi. 10.3390/cancers13164239
- By:
- Publication type:
- Article
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E269, doi. 10.1002/ajh.26201
- By:
- Publication type:
- Article
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E306, doi. 10.1002/ajh.26235
- By:
- Publication type:
- Article
Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Cancers, 2021, v. 13, n. 15, p. 3856, doi. 10.3390/cancers13153856
- By:
- Publication type:
- Article
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 326, doi. 10.1002/hon.2861
- By:
- Publication type:
- Article
Targeting HIF-1α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL.
- Published in:
- Cancers, 2021, v. 13, n. 12, p. 2883, doi. 10.3390/cancers13122883
- By:
- Publication type:
- Article
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. E168, doi. 10.1002/ajh.26127
- By:
- Publication type:
- Article
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 4, p. 493, doi. 10.1111/ejh.13573
- By:
- Publication type:
- Article
Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 4, p. 249, doi. 10.3390/jpm11040249
- By:
- Publication type:
- Article
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.594556
- By:
- Publication type:
- Article
Editorial: CAR T-Cell Therapies in Hematologic Tumors.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy.
- Published in:
- Cancers, 2020, v. 12, n. 7, p. 1773, doi. 10.3390/cancers12071773
- By:
- Publication type:
- Article
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.00888
- By:
- Publication type:
- Article
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.
- Published in:
- Cancers, 2020, v. 12, n. 2, p. 282, doi. 10.3390/cancers12020282
- By:
- Publication type:
- Article
Venetoclax in CLL patients who progress after B‐cell Receptor inhibitor treatment: a retrospective multi‐centre Italian experience.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 1, p. e8, doi. 10.1111/bjh.16123
- By:
- Publication type:
- Article
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.
- Published in:
- 2019
- By:
- Publication type:
- letter
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S278, doi. 10.1016/j.clml.2019.07.213
- By:
- Publication type:
- Article
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.
- Published in:
- Cancers, 2019, v. 11, n. 7, p. 896, doi. 10.3390/cancers11070896
- By:
- Publication type:
- Article
Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 5, p. 703, doi. 10.1111/ejh.13149
- By:
- Publication type:
- Article
LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S213, doi. 10.1016/j.clml.2018.07.075
- By:
- Publication type:
- Article
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow‐up.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 5, p. 693, doi. 10.1111/bjh.14681
- By:
- Publication type:
- Article
Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.
- Published in:
- Journal of Immunology Research, 2017, p. 1, doi. 10.1155/2017/1832968
- By:
- Publication type:
- Article
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 4, p. 306, doi. 10.1111/ejh.12918
- By:
- Publication type:
- Article
The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S42, doi. 10.1016/j.clml.2016.07.060
- By:
- Publication type:
- Article
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 4, p. 1, doi. 10.1371/journal.pone.0060975
- By:
- Publication type:
- Article
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
- Published in:
- Cellular & Molecular Life Sciences, 2011, v. 68, n. 14, p. 2419, doi. 10.1007/s00018-011-0704-8
- By:
- Publication type:
- Article
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.
- Published in:
- Journal of Cellular & Molecular Medicine, 2010, v. 14, n. 12, p. 2803, doi. 10.1111/j.1582-4934.2009.00926.x
- By:
- Publication type:
- Article
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells.
- Published in:
- European Journal of Immunology, 2005, v. 35, n. 4, p. 1155, doi. 10.1002/eji.200425093
- By:
- Publication type:
- Article
Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.
- Published in:
- British Journal of Haematology, 2001, v. 113, n. 4, p. 1051, doi. 10.1046/j.1365-2141.2001.02871.x
- By:
- Publication type:
- Article
Increased expression of non-functional killer inhibitory receptor CD94 in CD8<sup>+</sup> cells of myeloma patients.
- Published in:
- British Journal of Haematology, 2000, v. 109, n. 1, p. 46, doi. 10.1046/j.1365-2141.2000.01981.x
- By:
- Publication type:
- Article